Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.52 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | SIK1 | P57059 | 2/20 | 0.46 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.46 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 7/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487646 | 0.95 | LCK (0.52) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4490742 | 0.92 | LCK (0.56) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4496550 | 0.92 | LCK (0.61) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4494896 | 0.91 | LCK (0.62) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4507099 | 0.91 | TNK2 (0.54) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4485553 | 0.91 | LCK (0.50) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4487521 | 0.90 | TNK2 (0.52) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4487014 | 0.90 | LCK (0.51) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4498854 | 0.89 | TNK2 (0.52) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4496235 | 0.89 | LCK (0.52) | LCKTNK2BTKJAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | LCK 33/4885TNK2 1854/4885BTK 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.